Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations

References

• WHO. The top 10 causes of death. World Health Organization; 2018 May 24. Available from: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
   Google Scholar
• Dransfield MT, Kunisaki KM, Strand MJ, et al. COPDGene investigators. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care M:ed. 2017;195:324–330.
   PubMed Web of Science ®Google Scholar
• Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicon Econ Outcomes Res. 2013;5:235–245.
   PubMedGoogle Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017 Mar 1;195(5):557–582.
   PubMed Web of Science ®Google Scholar
• Celli BR. Pathophysiology of chronic obstructive pulmonary disease. In: Aliverti A, Brusasco V, Macklem PT, et al., editors. Mechanics of breathing. Milano: Springer; 2002;218-231.
   Google Scholar
• Nixon J, Newbold P, Mustelin T, et al. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther. 2017;169:57–77.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Bagnasco D, Borriello F, et al. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol. 2016;16(2):186–200.
   PubMed Web of Science ®Google Scholar
• Couillard S, Larivee P, Courteau J, et al. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366–373.
   PubMed Web of Science ®Google Scholar
• Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964–971.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2000 Oct 28;356(9240):1480–1485.
   PubMed Web of Science ®Google Scholar
• Keating GM. Mepolizumab: first global approval. Drugs. 2015;75:2163–2169.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Nucala (mepolizumab) for injection, for subcutaneous use; 2017. [cited 2018 Jul 2]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDF
   Google Scholar
• Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, and anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011;50(4):215–227.
   PubMed Web of Science ®Google Scholar
• Hall S, Agrawal DK. Key mediators in the immunopathogenesis of allergic asthma. Int Immunopharmacol. 2014;23(1):316–329.
   PubMed Web of Science ®Google Scholar
• Hart TK, Cook RM, Zia-Amirhosseine P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108(2):250–257.
   PubMed Web of Science ®Google Scholar
• Hait AE, Hart T, North S, et al. Mepolizumab investigator’s brochure. Brentford: GlaxoSmithKline; 2008. (Data on file).
   Google Scholar
• Zia-Amirhosseini P, Minthorn E, Benincosa LJ, et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther. 1999;291(3):1060–1067.
   PubMed Web of Science ®Google Scholar
• Ortega H, Yancey S, Cozens S. Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites. Clin Pharmacol Drug Dev. 2013;3(1):57–62.
   PubMed Web of Science ®Google Scholar
• Barnes P, Holgate ST, Stark PJ. A double blind, placebo controlled, dose rising study to assess safety, pharmacokinetics and effect on the early and late phase response to allergen challenge of SB-240563 in male patients with mild asthma. Brentford: GlaxoSmithKline; 1999. (Data on file).
   Google Scholar
• Freestone S. A double blind, placebo controlled, dose rising study to assess safety and pharmacokinetics of SB-240563 in male patients with mild asthma. Brentford: GlaxoSmithKline; 1998. (Data on file).
   Google Scholar
• Freestone S. A double blind, placebo controlled, parallel group study to assess the tolerability and pharmacokinetics of three 250 mg subcutaneous doses of SB-240563 in male and female patients with asthma. Brentford: GlaxoSmithKline; 2001. (Data on file).
   Google Scholar
• Dasgupta A, Kjarsgaard M, Capaldi D, et al. A pilot randomized clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J. 2017 March;49(3):1602486.
   PubMed Web of Science ®Google Scholar
• Yancey S, Albers F, Gunsoy N, et al. Effect of mepolizumab on exacerbations in asthma patients with features common in COPD abstract. Am J Respir Crit Care Med. 2017;195:A4683.
   Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017 Oct 26;377(17):1613–1629. Epub 2017 Sep 11.
   PubMed Web of Science ®Google Scholar
• Chapman K, Pavord I, Paggiaro P, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease (COPD): a meta-analysis of METREX and METREO patient-reported outcomes, response to therapy and lung function. Am J Respir Crit Care Med. 2018;197:A4230.
   Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. SIRIUS investigators oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197.
   PubMed Web of Science ®Google Scholar
• Burden of Disease Among Subjects with Eosinophilic Chronic Obstructive Pulmonary Disease (COPD) - Full Text View. Search of: Spain - List Results - ClinicalTrials.gov, clinicaltrials.gov/ct2/show/NCT03436511.
   Google Scholar
• Hoenderdos K, Condliffe A. The neutrophil in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2013;48:531–539.
   PubMed Web of Science ®Google Scholar
• McGeachie MJ, Yates KP, Zhou X, et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med. 2016;374(19):1842–1852.
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016 Feb;47(2):410–419. .
   PubMed Web of Science ®Google Scholar
• GSK reports on outcome of the FDA advisory committee on mepolizumab for the treatment of COPD patients on maximum inhaled therapy. GSK [cited 2018 Jul 25]. Available from: www.gsk.com/en-gb/media/press-releases/gsk-reports-on-outcome-of-the-fda-advisory-committee-on-mepolizumab-for-the-treatment-of-copd-patients-on-maximum-inhaled-therapy/
   Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomized, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891–901.
   PubMed Web of Science ®Google Scholar
• Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease with Exacerbation History (GALATHEA). ClinicalTrials.gov Identifier: NCT02138916.
   Google Scholar
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (TERRANOVA). ClinicalTrials.gov Identifier: NCT02155660.
   Google Scholar